Tasly Pharmaceutical Group Co., Ltd (SHA: 600535)
China
· Delayed Price · Currency is CNY 15.59
-0.13 (-0.83%)
Nov 13, 2024, 3:00 PM CST
Tasly Pharmaceutical Group Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 8,527 | 8,636 | 8,606 | 7,898 | 13,505 | 18,932 | Upgrade
|
| Other Revenue | 37.71 | 37.71 | 31.19 | 53.86 | 70.82 | 65.83 | Upgrade
|
| Revenue | 8,565 | 8,674 | 8,637 | 7,952 | 13,576 | 18,998 | Upgrade
|
| Revenue Growth (YoY) | -5.63% | 0.42% | 8.62% | -41.43% | -28.54% | 5.61% | Upgrade
|
| Cost of Revenue | 2,852 | 2,885 | 3,147 | 2,682 | 8,115 | 13,056 | Upgrade
|
| Gross Profit | 5,713 | 5,789 | 5,490 | 5,269 | 5,461 | 5,943 | Upgrade
|
| Selling, General & Admin | 3,321 | 3,326 | 3,267 | 3,339 | 3,215 | 3,405 | Upgrade
|
| Research & Development | 923.72 | 917.27 | 845.34 | 579.53 | 689.33 | 551.22 | Upgrade
|
| Other Operating Expenses | 100.08 | 97.62 | 37.96 | 110.64 | 104.05 | 139.29 | Upgrade
|
| Operating Expenses | 4,349 | 4,349 | 4,149 | 4,027 | 4,073 | 4,095 | Upgrade
|
| Operating Income | 1,363 | 1,440 | 1,341 | 1,243 | 1,388 | 1,848 | Upgrade
|
| Interest Expense | -75.6 | -82.52 | -64.86 | -77.39 | -286.69 | -451.08 | Upgrade
|
| Interest & Investment Income | 106.07 | 107.55 | 107.55 | 1,792 | 241.04 | 33.51 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.23 | -1.23 | -1.61 | 7.27 | 5.58 | -5.3 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.41 | -4.73 | -71.11 | 0 | -11.05 | -12.06 | Upgrade
|
| EBT Excluding Unusual Items | 1,391 | 1,459 | 1,311 | 2,965 | 1,337 | 1,413 | Upgrade
|
| Impairment of Goodwill | - | - | -151.2 | - | -59.01 | -33.03 | Upgrade
|
| Gain (Loss) on Sale of Investments | -380.99 | -282.81 | -1,125 | -79.88 | 118.21 | -169.77 | Upgrade
|
| Gain (Loss) on Sale of Assets | -1.3 | -1.63 | -4.93 | 41.27 | -5.67 | -1.34 | Upgrade
|
| Asset Writedown | -41.86 | - | -194.64 | -262.53 | - | -19.18 | Upgrade
|
| Other Unusual Items | 46.67 | 46.67 | -1.96 | 60.04 | 66.91 | 141.21 | Upgrade
|
| Pretax Income | 1,014 | 1,221 | -167.63 | 2,724 | 1,457 | 1,331 | Upgrade
|
| Income Tax Expense | 169.11 | 204.46 | 180.82 | 315.92 | 367.2 | 327.63 | Upgrade
|
| Earnings From Continuing Operations | 844.68 | 1,017 | -348.46 | 2,408 | 1,090 | 1,003 | Upgrade
|
| Minority Interest in Earnings | 36.38 | 54.43 | 84.22 | -48.75 | 36.03 | -1.74 | Upgrade
|
| Net Income | 881.05 | 1,071 | -264.24 | 2,359 | 1,126 | 1,001 | Upgrade
|
| Net Income to Common | 881.05 | 1,071 | -264.24 | 2,359 | 1,126 | 1,001 | Upgrade
|
| Net Income Growth | -20.77% | - | - | 109.51% | 12.43% | -35.19% | Upgrade
|
| Shares Outstanding (Basic) | 1,500 | 1,494 | 1,468 | 1,502 | 1,501 | 1,517 | Upgrade
|
| Shares Outstanding (Diluted) | 1,500 | 1,494 | 1,468 | 1,502 | 1,501 | 1,517 | Upgrade
|
| Shares Change (YoY) | 2.18% | 1.77% | -2.29% | 0.08% | -1.06% | 0.16% | Upgrade
|
| EPS (Basic) | 0.59 | 0.72 | -0.18 | 1.57 | 0.75 | 0.66 | Upgrade
|
| EPS (Diluted) | 0.59 | 0.72 | -0.18 | 1.57 | 0.75 | 0.66 | Upgrade
|
| EPS Growth | -22.47% | - | - | 109.33% | 13.64% | -35.29% | Upgrade
|
| Free Cash Flow | 2,033 | 1,907 | 1,875 | 2,229 | 1,382 | 949.37 | Upgrade
|
| Free Cash Flow Per Share | 1.36 | 1.28 | 1.28 | 1.48 | 0.92 | 0.63 | Upgrade
|
| Dividend Per Share | 0.590 | 0.330 | 0.330 | 0.330 | 0.330 | 0.330 | Upgrade
|
| Dividend Growth | 78.79% | 0% | 0% | 0% | 0% | 10.00% | Upgrade
|
| Gross Margin | 66.70% | 66.74% | 63.56% | 66.27% | 40.23% | 31.28% | Upgrade
|
| Operating Margin | 15.92% | 16.60% | 15.52% | 15.63% | 10.22% | 9.73% | Upgrade
|
| Profit Margin | 10.29% | 12.35% | -3.06% | 29.66% | 8.29% | 5.27% | Upgrade
|
| Free Cash Flow Margin | 23.74% | 21.98% | 21.71% | 28.04% | 10.18% | 5.00% | Upgrade
|
| EBITDA | 1,759 | 1,852 | 1,774 | 1,648 | 1,927 | 2,235 | Upgrade
|
| EBITDA Margin | 20.54% | 21.35% | 20.54% | 20.72% | 14.20% | 11.76% | Upgrade
|
| D&A For EBITDA | 395.93 | 412.21 | 433.92 | 405.08 | 539.67 | 386.72 | Upgrade
|
| EBIT | 1,363 | 1,440 | 1,341 | 1,243 | 1,388 | 1,848 | Upgrade
|
| EBIT Margin | 15.92% | 16.60% | 15.52% | 15.63% | 10.22% | 9.73% | Upgrade
|
| Effective Tax Rate | 16.68% | 16.74% | - | 11.60% | 25.20% | 24.62% | Upgrade
|
| Revenue as Reported | 8,565 | 8,674 | 8,637 | - | 13,576 | 18,998 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.